Calidi Biotherapeutics, Inc.
CLDI
$0.415
-$0.016-3.71%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.31% | -1.18% | 9.60% | 11.29% | -0.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.89% | -1.75% | 14.04% | 27.60% | 24.04% |
| Operating Income | 24.89% | 1.75% | -14.04% | -27.60% | -24.28% |
| Income Before Tax | 23.99% | 8.51% | 27.58% | -24.14% | -14.89% |
| Income Tax Expenses | -12.50% | -50.00% | 233.33% | 23.08% | 45.45% |
| Earnings from Continuing Operations | 23.98% | 8.53% | 27.53% | -24.14% | -14.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.21% | 8.59% | 27.53% | -24.14% | -14.90% |
| EBIT | 24.89% | 1.75% | -14.04% | -27.60% | -24.28% |
| EBITDA | 25.27% | 1.81% | -14.16% | -27.53% | -23.98% |
| EPS Basic | 82.92% | 80.15% | 80.67% | 20.04% | -18.91% |
| Normalized Basic EPS | 83.96% | 83.48% | 83.62% | 29.00% | -8.98% |
| EPS Diluted | 82.92% | 80.15% | 80.67% | 20.04% | -18.91% |
| Normalized Diluted EPS | 83.96% | 83.48% | 83.62% | 29.00% | -8.98% |
| Average Basic Shares Outstanding | 374.83% | 402.77% | 301.39% | 103.99% | 16.80% |
| Average Diluted Shares Outstanding | 374.83% | 402.77% | 301.39% | 103.99% | 16.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |